ES2174275T3 - Uso de un derivado de deshidroepiandrosterona para acelera o incrementar la regeneracion del epitelio o la regeneracion del endotelio de un tejido. - Google Patents

Uso de un derivado de deshidroepiandrosterona para acelera o incrementar la regeneracion del epitelio o la regeneracion del endotelio de un tejido.

Info

Publication number
ES2174275T3
ES2174275T3 ES97936184T ES97936184T ES2174275T3 ES 2174275 T3 ES2174275 T3 ES 2174275T3 ES 97936184 T ES97936184 T ES 97936184T ES 97936184 T ES97936184 T ES 97936184T ES 2174275 T3 ES2174275 T3 ES 2174275T3
Authority
ES
Spain
Prior art keywords
sanguine
laguine
epitelization
laes
regeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97936184T
Other languages
English (en)
Inventor
Barbara A Araneo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/695,769 external-priority patent/US5929060A/en
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Application granted granted Critical
Publication of ES2174275T3 publication Critical patent/ES2174275T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL USO DE UN DERIVADO DE LA DESHIDROEPIANDROSTERONA (DHEA), TAL COMO AQUI SE DESCRIBE, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, PARA LA PREPARACION DE UNA COMPOSICION FARMACEUTICA QUE ACELERA LA RE-EPITELIZACION O RE-ENDOTELIZACION DISULAR EN UN SUJETO QUE LA NECESITA. ENTRE EJEMPLOS DE RE-EPITELIZACION PARA LAS QUE ES PARTICULARMENTE ADECUADA LA INVENCION SE INCLUYEN, SIN QUE LA ENUMERACION QUE SIGUE SEA LIMITATIVA, LA RE-EPITELIZACION DE (A) LA PIEL DESPUES DE HERIDAS QUIRURGICAS; (B) LAS ABRASIONES CUTANEAS PROVOCADAS POR TRAUMA MECANICO, AGENTES CAUSTICOS O QUEMADURAS; (C) LA CORNEA DESPUES DE OPERACION DE CATARATA O TRASPLANTE DE CORNEA; (D) EL EPITELIO MUCOSO (TEJIDO RESPIRATORIO, GASTROINTESTINAL, GENITOURINARIO, MAMARIO, DE LA CAVIDAD ORAL, OCULAR, HIGADO Y RIÑON) DESPUES DE INFECCION, ETIOLOGIAS NO PATOLOGICAS DE TERAPIA MEDICAMENTOSA; (E) PIEL DESPUES DE INJERTO; Y (F) TUBULOS RENALES DESPUES DE NECROSIS TUBULAR AGUDA. ENTRE LOS EJEMPLOSDE REENDOTELIZACION PARA LOS QUE LA INVENCION ES PARTICULARMENTE APROPIADA SE INCLUYEN, SIN QUE LA ENUMERACION QUE SIGUE DEBA INTERPRETARSE DE FORMA LIMITATIVA, LA RE-ENDOTELIZACION (O EL RECRECIMIENTO DEL ENDOTELIO) EN VASOS SANGUINEOS DESPUES DE ANGIOPLASTIA, Y LA LISIS DE COAGULOS DE FIBRINA O LA LISIS O ALTERACION MECANICA DE TROMBOS EN ARTERIAS CORONARIAS. SEGUN LA PRESENTE INVENCION, EL TIEMPO NECESARIO PARA UNA COMPLETA REEPITELIZACION O RE-ENDOTELIZACION MEJORA O SE ACELERA POR ADMINISTRACION DE UN DERIVADO DE LA DESHIDROEPIANDROSTERONA (DHEA).
ES97936184T 1996-08-01 1997-07-31 Uso de un derivado de deshidroepiandrosterona para acelera o incrementar la regeneracion del epitelio o la regeneracion del endotelio de un tejido. Expired - Lifetime ES2174275T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/695,769 US5929060A (en) 1992-05-01 1996-08-01 Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue
US86917797A 1997-06-05 1997-06-05
US08/901,085 US5922701A (en) 1992-05-01 1997-07-28 Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue

Publications (1)

Publication Number Publication Date
ES2174275T3 true ES2174275T3 (es) 2002-11-01

Family

ID=27418624

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97936184T Expired - Lifetime ES2174275T3 (es) 1996-08-01 1997-07-31 Uso de un derivado de deshidroepiandrosterona para acelera o incrementar la regeneracion del epitelio o la regeneracion del endotelio de un tejido.

Country Status (10)

Country Link
US (1) US5922701A (es)
EP (1) EP0915702B1 (es)
JP (1) JP2002514168A (es)
AT (1) ATE216242T1 (es)
AU (1) AU713850B2 (es)
CA (1) CA2262086C (es)
DE (1) DE69712065T2 (es)
DK (1) DK0915702T3 (es)
ES (1) ES2174275T3 (es)
WO (1) WO1998005338A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091155A1 (en) * 1995-06-22 2002-07-11 Btg Pharmaceutical Corp. Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1
US6576659B1 (en) * 1996-12-05 2003-06-10 Bio-Technology General Corp. Use of oxandrolone in the treatment of burns an other wounds
EP0908183A1 (en) * 1997-10-08 1999-04-14 Institute For Advanced Skin Research Inc. Dehydroepiandrosterone or derivatives thereof for increasing the content of hyaluronic acid in skin
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20080015174A1 (en) * 1998-11-24 2008-01-17 Reading Christopher L Metabolic Disease Treatments
EP1832598A3 (en) 1999-09-30 2008-01-02 Hollis-Eden Pharmaceuticals Inc. Therapeutic treatment of androgen receptor driven conditions
FR2803750B1 (fr) * 2000-01-17 2004-04-02 Assist Publ Hopitaux De Paris Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs biologiques et de ses derives metaboliques comme anti-atrophiant
US6882879B2 (en) 2000-07-19 2005-04-19 Innovamedica S.A. De C.V. Impedance spectroscopy system and catheter for ischemic mucosal damage monitoring in hollow viscous organs
FR2831440B1 (fr) * 2001-10-25 2003-12-26 Oreal Composition cosmetique, renfermant un derive de la dhea et un agent apaisant
US20040121991A1 (en) * 2002-12-20 2004-06-24 Araneo Barbara A. Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers
EP1615944A4 (en) * 2003-04-01 2010-08-11 Harbor Biosciences Inc ANTI-ORANGE PROBLEMS WITH MARGINAL AGONIST EFFECT AND METHOD OF USE
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
CA2582231A1 (en) * 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
US20060073099A1 (en) * 2004-10-01 2006-04-06 Frincke James M Treatment screening methods
US8758838B2 (en) 2005-08-31 2014-06-24 Johnson & Johnson Consumer Companies, Inc. Anti-inflammatory compositions and methods of use
US8697152B2 (en) 2005-08-31 2014-04-15 Johnson & Johnson Consumer Companies, Inc. Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract
CN102215845A (zh) * 2008-04-03 2011-10-12 哈博生物科学公司 药学试剂的固体形式
WO2009149392A1 (en) 2008-06-06 2009-12-10 Hollis-Eden Pharmaceuticals, Inc. Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
JPWO2023068376A1 (es) * 2021-10-22 2023-04-27

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001119A (en) * 1987-11-25 1991-03-19 Schwartz Arthur G 16-substituted androstanes and 16-substituted androstenes
US4898694A (en) * 1987-11-25 1990-02-06 Schwartz Arthur G 17-Hydroxy-steroids
US5175154A (en) * 1987-11-25 1992-12-29 Research Corporation Technologies, Inc. 5 α-pregnan-20-ones and 5-pregnen-20-ones and related compounds
US5162198A (en) * 1991-02-08 1992-11-10 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation
US5110810A (en) * 1991-02-08 1992-05-05 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of platelet aggregation
NZ252491A (en) * 1992-05-01 1997-05-26 Univ Utah Compositions of dhea (dehydroepiandrosterone) congeners to treat abnormally elevated il-6 levels
US5686438A (en) * 1993-03-09 1997-11-11 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5635496A (en) * 1993-03-09 1997-06-03 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5587369A (en) * 1993-03-09 1996-12-24 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
AU677308B2 (en) * 1993-03-09 1997-04-17 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
FR2729854A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation du sulfate de dehydroepi-androsterone dans une composition cosmetique ou dermatologique

Also Published As

Publication number Publication date
ATE216242T1 (de) 2002-05-15
WO1998005338A2 (en) 1998-02-12
WO1998005338A3 (en) 1998-03-26
DK0915702T3 (da) 2002-08-12
US5922701A (en) 1999-07-13
AU3891797A (en) 1998-02-25
JP2002514168A (ja) 2002-05-14
CA2262086A1 (en) 1998-02-12
EP0915702B1 (en) 2002-04-17
AU713850B2 (en) 1999-12-09
DE69712065T2 (de) 2002-11-07
DE69712065D1 (de) 2002-05-23
EP0915702A2 (en) 1999-05-19
CA2262086C (en) 2003-11-11

Similar Documents

Publication Publication Date Title
ES2174275T3 (es) Uso de un derivado de deshidroepiandrosterona para acelera o incrementar la regeneracion del epitelio o la regeneracion del endotelio de un tejido.
de RÖTTH Plastic repair of conjunctival defects with fetal membranes
AR018717A1 (es) COMPUESTOS DERIVADOS DE PIPERIDINA, SU USO, UN PROCESO PARA SU PREPARACIoN, COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN, Y COMPUESTOS INTERMEDIARIOS.
Sparks et al. Early benefits of subfascial endoscopic perforator surgery (SEPS) in healing venous ulcers
PE20240657A1 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos medicos
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
Scheffel et al. Immediate human pulp response to ethanol-wet bonding technique
AR009028A1 (es) Composiciones farmaceuticas, un procedimiento para preparar dichas composiciones y utilizacion de dichas composiciones en el tratamiento deenfermedades oftalmicas y metodos para tratar dichas enfermedades
RU2008143248A (ru) Применение производных холест-4-ен-3-она для получения цитопротекторного лекарственного средства
AR037556A1 (es) Composicion farmaceutica que comprende un abridor del canal de c1c-2
AR014964A1 (es) Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones
Alwmark et al. Emergency and long-term transesophageal sclerotherapy of bleeding esophageal varices: a prospective study of 50 consecutive cases
ES2087623T3 (es) Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon.
GINGRASS et al. Complications with the deltopectoral flap
AR006345A1 (es) Una composicion farmaceutica para administracion oral que comprende un inhibidor de proteasa del vih y un derivado de tocoferol soluble en agua, y un metodo para preparar dicha composicion.
Mundy et al. Creation of free flaps by arterialization of the venous system
US5994399A (en) Method of regenerating collagen-containing tissues with misoprostol
Dunsche et al. Use of carbon dioxide laser in the therapy of benign oral soft-tissue lesions
Calligaro et al. Management of lower extremity infected arterial grafts
CL2024000001A1 (es) Composición farmacéutica oral para prevenir y/o tratar enfermedades de los tejidos blandos y duros.
Prasad et al. Non‐suture intestinal anastomosis by invagination
Campbell Congenital polycystic disease of the kidneys and liver
McCARTHY RECENT DEVELOPMENTS IN THE SURGICAL MANAGEMENT OF THE OBSTRUCTING PROSTATE: CLINICAL LECTURE AT NEW YORK SESSION
PE20250003A1 (es) Composicion que comprende analogos de citidina y usos y metodos de la misma
UY39838A (es) Composición farmacéutica oral para prevenir y/o tratar enfermedades de los tejidos blandos y duros que rodean al diente en la cavidad bucal

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 915702

Country of ref document: ES